Table 1.
Selected trials currently enrolling patients or soon to open for AML featuring targeted agents
| Identifier | Phase | |
|---|---|---|
| IDH inhibitors | ||
| Frontline | ||
| Enasidenib or ivosidenib + 7 + 3, consolidation | NCT02632708 | 1 |
| Enasidenib or ivosidenib + azacytidine | NCT02677922 | 2 |
| Relapsed/refractory | ||
| Enasidenib vs conventional care salvage or BSC | NCT02577406 | 3 |
| FT-2102 + azacytidine | NCT02719574 | 1 |
| BAY1436032 | NCT03127735 | 1 |
| BCL2 antagonists | ||
| Frontline | ||
| Venetoclax + HMA | NCT02993523 | 3 |
| Venetoclax + LDAC | NCT03069352 | 3 |
| Relapsed/refractory | ||
| Venetoclax + idasnutlin or cobimetinib | NCT02670044 | 1/2 |
| FLT3 inhibitors | ||
| Frontline | ||
| Quizartinib + 7 + 3, HiDAC, +/− HSCT | NCT02668653 | 3 |
| Gilteritinib + 7 + 3, HiDAC +/− HSCT | NCT02236013 | 2 |
| Crenolanib + 7 + 3, HiDAC +/− HSCT | NCT02283177 | 2 |
| Gilteritinib ± azacitidine | NCT02752035 | 3 |
| Quizartinib + azacitidine or LDAC | NCT01892371 | 2 |
| Sorafenib + azacitidine | NCT02196857 | 2 |
| Maintenance | ||
| Gilteritinib postconsolidation | NCT02927262 | 3 |
| Gilteritinib post-HSCT | NCT02997202 | 3 |
| Midostaurin post-HSCT | NCT01883362 | 2 |
| Relapsed/refractory | ||
| Quizartinib vs conventional salvage | NCT02039726 | 3 |
| Gilteritinib vs conventional salvage | NCT02421939 | 3 |
| Crenolanib + HiDAC/mitoxantrone | NCT02298166 | 3 |
| E6201 | NCT02418000 | 1/2 |
| FF10101-01 | NCT03194685 | 1/2 |
| Splicing modulators | ||
| H3B-8800 | NCT02841540 | 1 |
| Novel HMAs | ||
| Postremission therapy | ||
| CC-486 | NCT01757535 | 3 |
| Relapsed/refractory | ||
| Guadecitabine | NCT02920008 | 3 |
| BET inhibitors | ||
| FT-1101 | NCT02543879 | 1 |
| CPI-0610 | NCT02158858 | 1 |
| GSK525762 | NCT01943851 | 1 |
| RO6870810 | NCT02308761 | 1 |
| MK-8628 | NCT02698189 | 1 |
| ABBV-075 + venetoclax | NCT02391480 | 1 |
| LSD1 inhibitors | ||
| Tranylcypromine + ATRA | NCT02261779 | 1/2 |
| GSK2879552 | NCT02177812 | 1 |
| INCB059872 | NCT02712905 | 1/2 |
| IMG-7289 + ATRA | NCT02842827 | 1 |
| HDAC inhibitors | ||
| Pracinostat + 5-azacitidine | NCT03151408 | 3 |
| Entinostat + 5-azacitidine | NCT01305499 | 2 |
| Panobinostat + fludarabine + cytarabine | NCT02676323 | 1 |
| ADCs | ||
| Frontline | ||
| SL-401 + azacytidine | NCT03113643 | 1 |
| Relapsed/refractory | ||
| SL-401 | NCT02113982 | 2 |
| SGN-123A | NCT02848248 | 1 |
| Postremission therapy | ||
| SL-401 | NCT02270463 | 1/2 |
7 + 3, continuous infusion cytarabine (7 doses) plus anthracycline (3 doses); HDAC, histone deacetylase; HSCT, hematopoietic stem cell transplant.